CEO Matthew Angel Increases Stake to 37.4% and Invests $500K in Private Placement
Summary
CEO Matthew Angel, through Factor Bioscience Inc., acquired an additional $500,001 in shares and warrants as part of a recent private placement, increasing his beneficial ownership to 37.4% of Tempest Therapeutics.
Key Events
-
CEO's Increased Ownership
Matthew Angel now beneficially owns 5,531,516 shares, representing 37.4% of the company's outstanding common stock.
-
Private Placement Investment
Through Factor Bioscience Inc., Mr. Angel invested $500,001.12 in the company's recent private placement on March 24, 2026, acquiring 231,482 shares and warrants for an additional 462,964 shares.
-
Asset Acquisition Details
The filing provides further context on the February 3, 2026, acquisition of 4,837,070 shares by Mr. Angel via the Asset Purchase Agreement, which was initially dated November 19, 2025.
Analysis
This Schedule 13D/A details a significant increase in beneficial ownership by CEO Matthew Angel, primarily through his controlled entity, Factor Bioscience Inc. His participation in the recent private placement, investing over $500,000, demonstrates strong insider conviction in the company's future. This capital infusion, coupled with his substantial 37.4% stake, provides a positive signal for investors, especially for a small life sciences company where funding and leadership alignment are critical. The filing also clarifies the prior asset acquisition and associated share issuance.
At the time of this filing, TPST was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.5M. The 52-week trading range was $1.65 to $12.23. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.